While demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical.
Vaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico.
That help is still months away, however. The company says it plans to seek authorization for the shots in the U.S., Europe and elsewhere by the end of September and be able to produce up to 100 million doses a month by then. There were 77 cases of COVID-19 — 14 in the group that got the vaccine and the rest were in volunteers who received dummy shots. None in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.
Novavax reported the results in a press release and plans to publish in a medical journal, where it will be vetted by independent experts. The Maryland-based company previously released findings from smaller studies in Britain and South Africa.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
Read more »
Novavax COVID-19 vaccine more than 90% effective in U.S. trialNovavax Inc (NVAX.O) on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.
Read more »
Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.
Read more »
Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trialJUST IN: Novavax says its coronavirus vaccine has an overall efficacy of 90.4% and was 'generally well-tolerated' in a Phase 3 trial in the US and Mexico
Read more »
Novavax Covid vaccine highly effective in U.S. trials, including against variants, company saysNovavax said it plans to apply to the Food and Drug Administration for emergency use authorization in the third quarter.
Read more »
Reduced U.S. Covid-19 Data Reporting Worries Some Health ExpertsSome epidemiologists are concerned that lagging data will leave public-health leaders with blind spots as new variants of the coronavirus circulate and many parts of the world battle rising cases.
Read more »